Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28355393 | 0.81 | POLB (0.40) | POLBHTTEPHX1ALDH1A1MEN1 | |
| SCHEMBL11729650 | 0.79 | POLB (0.40) | POLBHTTEPHX1ALDH1A1MEN1 | |
| SCHEMBL6562571 | 0.77 | — | — | |
| SCHEMBL15679321 | 0.77 | POLB (0.40) | POLBHTTEPHX1ALDH1A1MEN1 | |
| SCHEMBL1484742 | 0.77 | — | — | |
| SCHEMBL10488605 | 0.76 | POLB (0.44) | POLBHTTEPHX1ALDH1A1MEN1 | |
| SCHEMBL3926071 | 0.75 | POLB (0.47) | POLBHTTEPHX1ALDH1A1MEN1 | |
| SCHEMBL28355392 | 0.75 | POLB (0.39) | POLBHTTEPHX1ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL4028674 | 0.75 | EPHX1 (0.34) | EPHX1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL16126013 | 0.75 | POLB (0.38) | POLBHTTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-0068590-B1 | NOVEL UREA DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | POLB 4518/4885HTT 583/4885EPHX1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.